PsychoactiveMap

Psychedelic and ketamine research trials in Italy

Curated snapshot as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap.

This is a dated selection from the broader clinical catalogue for Italy, not a complete inventory of research. The catalogue loads separately, may show cached records, and includes compounds and ketamine uses outside this hub's scope. Scope and update timing can produce different totals. Historical publications are separate from these registered-study counts.

5 registered studies are counted in Italy. By compound: 5 ketamine. By registry status: 4 recruiting and 1 completed. By phase: 1 phase 2, 3 phase 3 and 1 not reported. Reported start years run from 2017 (earliest) to 2026 (latest). Studies are linked to 22 source-listed facility records.

Country is taken from the research sites linked to each registry record. A study counts once per country and may appear in several countries. Compound counts may overlap. This directory covers its linked compound hubs; the research map and MCP connector also include other compounds. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.

Facility records may include aliases or departments of the same institution; they are not a count of unique institutions. A listed facility does not establish a sponsor, lead site or care provider role, or confirm recruitment.

Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.

Recruiting or not yet recruiting

4 of the 5 counted studies are listed in the registry as recruiting (4) or not yet recruiting (0), newest start first. Status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone; eligibility and contact details are on each registry record.

Title as registeredRegistry IDStatusPhaseRegistry datesSource-listed facility and city
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderNCT07227454RecruitingPhase 3Source start: 2026-01-08 (actual)
Source date details

Start: 2026-01-08 (precision: day; source type: ACTUAL; actual)

Primary completion: 2031-04-09 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2031-09-15 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:18.160Z; registry revision: 2026-09-25 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Presidio Ospedaliero Santa Marta e Santa Venera, Acireale; Azienda Ospedaliero Universitaria di Sassari, Sassari; Ospedale di Merano, Merano; Azienda Ospedaliera Universitaria Federico II, Naples; Azienda Ospedaliera G. Brotzu, Cagliari; AOU Meyer, Florence; Azienda Ospedaliera Universitaria Policlinico Riuniti di Foggia, Foggia; G.Gaslini Institute, Genova
Ketamine Augmentation of ECT in Treatment-Resistant DepressionNCT07088380RecruitingPhase 3Source start: 2025-07-10 (actual)
Source date details

Start: 2025-07-10 (precision: day; source type: ACTUAL; actual)

Primary completion: 2026-08 (precision: month; source type: ESTIMATED; estimated)

Study completion: 2026-09 (precision: month; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:18.089Z; registry revision: 2026-05-11 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

IRCCS Ospedale San Raffaele Turro, Milan
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.NCT05973851RecruitingPhase 3Source start: 2024-08-31 (actual)
Source date details

Start: 2024-08-31 (precision: day; source type: ACTUAL; actual)

Primary completion: 2028-06-30 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2028-06-30 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:16.980Z; registry revision: 2025-09-26 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Università degli studi della Campania Luigi Vanvitelli, Naples; University of Cagliari, Cagliari; Universita degli Studi di Brescia, Brescia; Azienda Ospedaliero-Universitaria "Città della Salute e della Scienza di Torino", Turin
Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant DepressionNCT07146503RecruitingNot reportedSource start: 2022-11-01 (actual)
Source date details

Start: 2022-11-01 (precision: day; source type: ACTUAL; actual)

Primary completion: 2026-07 (precision: month; source type: ESTIMATED; estimated)

Study completion: 2030-08 (precision: month; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:18.160Z; registry revision: 2026-03-31 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Csm Dds 8, Genova; Università di Chieti, Chieti; ASST Fatebenefratelli Sacco, Milan; Ospedale Policlinico San Martino, Genova; ASST Pavia, Pavia

At a glance

By compound

Compound hubStudies
Ketamine5

By registry status

StatusStudiesShare
Recruiting480%
Completed120%

By phase

PhaseStudiesShare
Phase 2120%
Phase 3360%
Not reported120%

Registry-listed start years

Start yearStudies
2024 and later3
2020 to 20231
2015 to 20191

All counted studies

All 5 counted studies, newest start first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.

Title as registeredRegistry IDStatusPhaseRegistry datesSource-listed facility and city
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderNCT07227454RecruitingPhase 3Source start: 2026-01-08 (actual)
Source date details

Start: 2026-01-08 (precision: day; source type: ACTUAL; actual)

Primary completion: 2031-04-09 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2031-09-15 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:18.160Z; registry revision: 2026-09-25 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Presidio Ospedaliero Santa Marta e Santa Venera, Acireale; Azienda Ospedaliero Universitaria di Sassari, Sassari; Ospedale di Merano, Merano; Azienda Ospedaliera Universitaria Federico II, Naples; Azienda Ospedaliera G. Brotzu, Cagliari; AOU Meyer, Florence; Azienda Ospedaliera Universitaria Policlinico Riuniti di Foggia, Foggia; G.Gaslini Institute, Genova
Ketamine Augmentation of ECT in Treatment-Resistant DepressionNCT07088380RecruitingPhase 3Source start: 2025-07-10 (actual)
Source date details

Start: 2025-07-10 (precision: day; source type: ACTUAL; actual)

Primary completion: 2026-08 (precision: month; source type: ESTIMATED; estimated)

Study completion: 2026-09 (precision: month; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:18.089Z; registry revision: 2026-05-11 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

IRCCS Ospedale San Raffaele Turro, Milan
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.NCT05973851RecruitingPhase 3Source start: 2024-08-31 (actual)
Source date details

Start: 2024-08-31 (precision: day; source type: ACTUAL; actual)

Primary completion: 2028-06-30 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2028-06-30 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:16.980Z; registry revision: 2025-09-26 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Università degli studi della Campania Luigi Vanvitelli, Naples; University of Cagliari, Cagliari; Universita degli Studi di Brescia, Brescia; Azienda Ospedaliero-Universitaria "Città della Salute e della Scienza di Torino", Turin
Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant DepressionNCT07146503RecruitingNot reportedSource start: 2022-11-01 (actual)
Source date details

Start: 2022-11-01 (precision: day; source type: ACTUAL; actual)

Primary completion: 2026-07 (precision: month; source type: ESTIMATED; estimated)

Study completion: 2030-08 (precision: month; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:18.160Z; registry revision: 2026-03-31 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Csm Dds 8, Genova; Università di Chieti, Chieti; ASST Fatebenefratelli Sacco, Milan; Ospedale Policlinico San Martino, Genova; ASST Pavia, Pavia
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for SuicideNCT03185819CompletedPhase 2Source start: 2017-10-05 (actual)
Source date details

Start: 2017-10-05 (precision: day; source type: ACTUAL; actual)

Primary completion: 2023-03-31 (precision: day; source type: ACTUAL; actual)

Study completion: 2023-03-31 (precision: day; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:14.289Z; registry revision: 2025-04-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

OSP RIUNITI-DIP Donna- Bambino, Foggia; Ospedale di Merano, Merano; Azienda Ospedaliera Universitaria Federico II, Naples; Azienda Ospedaliera Universitaria Policlinico G. Martino, Messina; Irccs Burlo-Garofalo, Trieste; Azienda Ospedaliera G. Brotzu, Cagliari; IRCCS C. Mondino, Istituto Neurologico Nazionale, Fondazione, Pavia

About this data

Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.

Substance hubs for these compounds

Ketamine

Condition hubs

Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.

Other country hubs

United States | Canada | Switzerland | United Kingdom | Israel | Brazil | France | China | Netherlands | Germany | Spain | Austria | Australia | Poland | Czech Republic | Ireland | Denmark | Sweden | Taiwan | Argentina | Belgium | Finland | Turkey | Greece | Hungary | Mexico | Bulgaria | Egypt | Norway | Pakistan | Portugal

All trial hubs | Learn | Disclaimer